» Articles » PMID: 19103987

Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages

Overview
Journal Circulation
Date 2008 Dec 24
PMID 19103987
Citations 75
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cannabinoid 1 (CB1) receptor blockade with rimonabant represents a clinical therapeutic strategy for obesity. Recently, the role of the endocannabinoid system has been described in peripheral organs. We sought to determine whether the endocannabinoid system could be involved in human atherosclerosis and whether CB1 receptor blockade could modulate proinflammatory activity in macrophages.

Methods And Results: mRNA expression levels of CB1 receptor in coronary atherectomy samples were significantly higher in patients with unstable angina than in those with stable angina (3.62+/-2.96-fold; n=7; P<0.05). Immunoreactive area analysis of the coronary artery showed that CB1 receptor expression was greater in lipid-rich atheromatous plaques than in fibrous plaques, especially in CD68 macrophages (9.5+/-1.2% versus 0.6+/-0.6%; n=5; P<0.01). Levels of blood endocannabinoids were significantly higher in patients with coronary artery disease (n=20) than those without coronary artery disease (n=20) (median [interquartile range]: anandamide, 1.048 pmol/mL [0.687 to 1.387 pmol/mL] versus 0.537 pmol/mL [0.468 to 0.857 pmol/mL], P<0.01; 2-arachidonoyl glycerol, 13.30 pmol/mL [6.65 to 16.21 pmol/mL] versus 7.67 pmol/mL [6.39 to 10.03 pmol/mL], P<0.05). In cultured macrophages, expression of CB1 receptor was significantly increased during monocyte-macrophage differentiation (1.78+/-0.13-fold; n=6; P<0.01). CB1 receptor blockade in macrophages induced a significant increase in cytosolic cAMP (29.9+/-13.0%; n=4; P<0.01), inhibited phosphorylation of c-Jun N-terminal kinase (-19.1+/-12.6%, n=4; P<0.05), and resulted in a significant decrease in the production of proinflammatory mediators (interleukin-1beta, -28.9+/-10.9%; interleukin-6, -24.8+/-7.6%; interleukin-8, -22.7+/-5.2%; tumor necrosis factor-alpha, -13.6+/-4.8%; matrix metalloproteinase-9, -16.4+/-3.8%; n=4 to 8; P<0.01).

Conclusions: Patients with coronary artery disease demonstrated the activation of the endocannabinoid system with elevated levels of blood endocannabinoids and increased expression of CB1 receptor in coronary atheroma. CB1 receptor blockade exhibited antiinflammatory effects on macrophages, which might provide beneficial effects on atherogenesis.

Citing Articles

The relationship between cannabis and cardiovascular disease: clearing the haze.

Chandy M, Jimenez-Tellez N, Wu J Nat Rev Cardiol. 2025; .

PMID: 39849111 DOI: 10.1038/s41569-025-01121-6.


Cannabis sativa extracts inhibit LDL oxidation and the formation of foam cells in vitro, acting as potential multi-step inhibitors of atherosclerosis development.

Musetti B, Kun A, Menchaca D, Rodriguez-Haralambides A, Varela J, Thomson L PLoS One. 2024; 19(12):e0310777.

PMID: 39705234 PMC: 11661628. DOI: 10.1371/journal.pone.0310777.


Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.

Bala K, Porel P, Aran K Psychopharmacology (Berl). 2024; 241(10):1939-1954.

PMID: 39264450 DOI: 10.1007/s00213-024-06683-w.


Pharmacology of Non-Psychoactive Phytocannabinoids and Their Potential for Treatment of Cardiometabolic Disease.

Wainwright C, Walsh S Handb Exp Pharmacol. 2024; 287():61-93.

PMID: 39235486 DOI: 10.1007/164_2024_731.


Potential perioperative cardiovascular outcomes in cannabis/cannabinoid users. A call for caution.

Echeverria-Villalobos M, Guevara Y, Mitchell J, Ryskamp D, Conner J, Bush M Front Cardiovasc Med. 2024; 11:1343549.

PMID: 38978789 PMC: 11228818. DOI: 10.3389/fcvm.2024.1343549.